Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD;
however, a significant proportion of patients at low risk of exacerbations are treated with …

Chronic obstructive pulmonary disease (COPD) is one of the leading global causes of
morbidity and mortality. A hallmark of COPD is progressive airflow obstruction primarily …

Background: North American and European health agencies recently warned of severe
breathing problems associated with gabapentinoids, including in patients with chronic …

Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma, but their role in
chronic obstructive pulmonary disease (COPD) is debated. Recent randomised controlled …

Rationale: Patients with chronic obstructive pulmonary disease (COPD) and type 2 diabetes
(T2D) have worse clinical outcomes compared with patients without metabolic …

Purpose Role of triple therapy in chronic obstructive pulmonary disease (COPD)
management is supported by growing evidence, but consensus is lacking on various …

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD)
recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …